BI
ELTX icon

BVF Inc’s Elicio Therapeutics ELTX Stock Holding History

BVF Inc’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-107,130
Closed -$621K – 69
2023
Q1 		$621K Hold
107,130
– – 0.02% 69
2022
Q4 		$869K Hold
107,130
– – 0.04% 74
2022
Q3 		$986K Hold
107,130
– – 0.04% 75
2022
Q2 		$1.22M Hold
107,130
– – 0.06% 74
2022
Q1 		$2.27M Hold
107,130
– – 0.09% 73
2021
Q4 		$3.11M Hold
107,130
– – 0.11% 73
2021
Q3 		$10.5M Buy
107,130
+3,480
+3% +$376K 0.41% 53
2021
Q2 		$13.5M Buy
103,650
+16,150
+18% +$2.33M 0.51% 46
2021
Q1 		$15.8M Buy
+87,500
New +$16.9M 0.59% 39

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.22B AUM 24.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BVF Inc's ELTX Position: Q2 2023 in Review

BVF Inc sold out of Elicio Therapeutics (ELTX) in Q2 2023, closing a stake of 107,130 shares — an estimated $621K sold.

BVF Inc first reported a position in ELTX in Q1 2021 and held it in 9 quarters. The position peaked at $15.8M in Q1 2021. 15 funds tracked by Wall St. Rank hold ELTX as of Q2 2023.

  • BVF Inc reported no remaining Elicio Therapeutics position as of Q2 2023 after selling out during the quarter.
  • BVF Inc sold 107,130 Elicio Therapeutics shares in Q2 2023, an estimated $621K.
  • BVF Inc first reported a position in Elicio Therapeutics in Q1 2021 and held it in 9 quarters.
  • BVF Inc's Elicio Therapeutics position peaked at $15.8M in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2023.

Based on BVF Inc's 13F filing for Q2 2023, filed 14 Aug 2023.